Navigation Links
Phase 3 Cystic Fibrosis Trial Results Presented at European Conference
Date:6/15/2009

SYDNEY, June 16 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) is pleased to announce that additional results of its recently completed international Phase III trial of Bronchitol in patients with cystic fibrosis have been presented at the 2009 European Cystic Fibrosis Conference in Brest, France.

The results were presented to the conference on Friday 12 June by Dr Diana Bilton of the Royal Brompton Hospital, London.

The trial was a multi-centre, randomised, double blind, placebo controlled, 26 week study, with an optional further 6 month open label uncontrolled period. It was conducted in 40 centres in the United Kingdom, Ireland, Australia and New Zealand.

The primary endpoint of the trial was to assess whether Bronchitol improves lung function as measured by a change in FEV1 when administered twice per day for six months.

The key secondary endpoint of the trial was to assess whether Bronchitol further improves lung function in patients already being treated with the most commonly used CF therapeutic, rhDNase. Additional endpoints included changes in the Forced Vital Capacity of the lung, pulmonary exacerbations and antibiotic use.

Safety evaluation included the incidence of adverse events and the microbiology of sputum samples.

    Clinical Results
    -- There was a clinically meaningful change from baseline (119mL) and
       placebo (93mL) at week 26 with Bronchitol for FEV1 (p<0.001).
       Importantly, treatment with Bronchitol showed an immediate and
       sustained improvement in lung function (FEV1) over the 26 weeks
       (p<0.001).
    -- For the subgroup of patients on concomitant rhDNase there was also a
       significant improvement in FEV1 from baseline (88mL) and from placebo
       (109mL) at we
'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 /PRNewswire/ -- China Cord Blood Corporation (NYSE: ... China,s leading provider of cord blood ... storage services, today announced that the Special Committee of the ... Houlihan Lokey ( China ) Limited as ... Hamilton LLP as its United States ...
(Date:6/2/2015)... June 2, 2015 MGB ... antibiotic resistance problem  MGB Biopharma, a ... anti-infectives, to address the major global problem of ... a stable intravenous (IV) formulation of MGB-BP-3, designed for ... infections.  The intravenous formulation of MGB-BP-3 ...
(Date:6/1/2015)... , June 1, 2015  Turing Pharmaceuticals ... Eliseo Oreste Salinas , MD, MSc,  has joined ... Dr. Salinas, who holds a medical ... brings a record of significant accomplishments in the ... Dr. Salinas has played a leadership ...
(Date:6/1/2015)... CHICAGO , June 1, 2015 /PRNewswire/ ... robust Decipher® genomic analysis platform, successfully classified ... the genomic expression of certain biomarkers, including ... chemotherapy. Importantly, this unique genomic signature has ... responsiveness to neoadjuvant chemotherapy in patients with ...
Breaking Biology Technology:China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4
... article, the City of Milwaukee has negotiated a three-year "franchise-like" ... company to start an Internet protocol video service to compete ... will be considered by the Milwaukee Common Council, AT&T would ... by the service. , , While there are ...
... big business (untold billions of dollars every year), they also ... of the fundamental ethical principle of informed consent ... is that conducting a clinical trial carries with it the ... positive or negative or even if the clinical trial is ...
... For the second time this year, a tech-based company in ... to the public. Called an initial public offering, this kind ... and investors who are directly involved, but to others who ... Madison-based biotechnology company, has filed papers with the Securities ...
Cached Biology Technology:State video franchises vs. universal service: Grasping the total picture 2State video franchises vs. universal service: Grasping the total picture 3State video franchises vs. universal service: Grasping the total picture 4What patients want: A story of choice, clinical trials & evidence-based medicine 2What patients want: A story of choice, clinical trials & evidence-based medicine 3What patients want: A story of choice, clinical trials & evidence-based medicine 4What patients want: A story of choice, clinical trials & evidence-based medicine 5Wisconsin IPOs are a harbinger of growing tech economy 2Wisconsin IPOs are a harbinger of growing tech economy 3
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
... To develop correctly, baby hearts need rhythm...even before they ... mechanical forces are important when making baby hearts," said ... a team of Vanderbilt engineers, scientists and clinicians attempting ... cells. In an article published last month in ...
... of engineers from universities in the U.S., Canada, and Qatar ... damage on bridges, stadiums and other large public infrastructure. ... government of Qatar, a Persian Gulf nation that has proposed ... three-member team is developing a wireless sensor network that will ...
... at The Wistar Institute have developed a mathematical method ... type of brain cancer, through variations in the way ... capable of predicting the subclasses of glioblastoma tumors ... could enable physicians to accurately predict which forms of ...
Cached Biology News:Baby hearts need rhythm to develop correctly 2Baby hearts need rhythm to develop correctly 3Baby hearts need rhythm to develop correctly 4Novel sensor system would flag structural weaknesses before bridges and stadiums collapse 2Wistar scientists develop gene test to accurately classify brain tumors 2Wistar scientists develop gene test to accurately classify brain tumors 3
... Collect eliminates manual data entry by collecting ... any Windows-based application. Collect is extremely ... hours of tedious data entry. An ... scales, pH meters, spectrophotometers, force gauges, digital ...
Mouse monoclonal [5H9] to RAD52 ( Abpromise for all tested applications). entrezGeneID: 5893 SwissProtID: P43351...
Purified anti-LAT...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Biology Products: